Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01225315 · ClinicalTrials.gov registry record · Phase 2
Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma
A Phase 2 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 438
- Enrollment target
NCT01225315: Completed Phase 2 study, sponsored by Idorsia Pharmaceuticals.
NCT01225315 is a Phase 2 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 438 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (229% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01225315, a Phase 2 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 438 participants
- Enrollment target
Study Summary
This study will assess the efficacy and safety of ACT-129968 in subjects with partly controlled asthma on reliever therapy only.
Interventions
- DRUG Placebo
- DRUG Setipiprant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 438 participants |
| Start Date | 2010-11-01 |
| Est. Completion | 2012-02-01 |
| Phase | Phase 2 |
What the finished NCT01225315 record still lists
NCT01225315 is an interventional study that assigns participants to a tested intervention. The registered 438 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (229% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01225315 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01225315 about?
NCT01225315 is a clinical study titled "Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma". This study will assess the efficacy and safety of ACT-129968 in subjects with partly controlled asthma on reliever therapy only.
What is the current status of trial NCT01225315?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 438 participants. The study started on 2010-11-01. Estimated completion is 2012-02-01.
What interventions are being tested in trial NCT01225315?
The interventions under investigation include: Placebo (DRUG), Setipiprant (DRUG).
Who is sponsoring clinical trial NCT01225315?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01225315's enrollment target sits among peer trials
438 89th of 2000 higher than 1,912 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05711446 · 438 participants · NA
Double Voiding and Post-transplant UTI
- NCT05421663 · 439 participants · Phase 1
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
- NCT06235151 · 439 participants · Phase 3
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI